Evidence map›Paper›PMID 21037568›Full record

ArticleNature genetics2010

A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3).

Victor Enciso-Mora, Peter Broderick, Yussanne Ma, Ruth F Jarrett, Henrik Hjalgrim, Kari Hemminki, Anke van den Berg, Bianca Olver, Amy Lloyd, Sara E Dobbins and 35 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 13 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 13 syntheses or guidelines pooled it, 195 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 10 institutions in 6 countries.

Victor Enciso-Mora *Section of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK.
Peter Broderick *Section of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK.
Yussanne Ma *Section of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK.
Ruth F JarrettInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G61 1QH, UK.
Henrik HjalgrimDepartment of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
Kari HemminkiDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany and Center for Primary Health Care Research, Clinical Research Center, Lund University, Malmö, Sweden.
Anke van den BergDepartment of Pathology & Medical Biology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Bianca OlverSection of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK.
Amy LloydSection of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK.
Sara E DobbinsSection of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK.
Tracy LightfootEpidemiology & Genetics Unit, Department of Health Sciences, University of York, York, YO10 5DD, UK.
Flora E van LeeuwenDepartment of Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Asta FörstiDivision of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany and Center for Primary Health Care Research, Clinical Research Center, Lund University, Malmö, Sweden.
Arjan DiepstraDepartment of Pathology & Medical Biology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Annegien BroeksDepartment of Experimental Therapy, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Jayaram VijayakrishnanSection of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK.
Lesley ShieldInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G61 1QH, UK.
Annette LakeInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G61 1QH, UK.
Dorothy MontgomeryInstitute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G61 1QH, UK.
Eve RomanEpidemiology & Genetics Unit, Department of Health Sciences, University of York, York, YO10 5DD, UK.
Andreas EngertUniversity Hospital of Cologne, Department of Internal Medicine, Cologne, Germany.
Elke Pogge von StrandmannUniversity Hospital of Cologne, Department of Internal Medicine, Cologne, Germany.
Katrin S ReinersUniversity Hospital of Cologne, Department of Internal Medicine, Cologne, Germany.
Ilja M NolteUnit of Genetic Epidemiology and Bioinformatics, Department of Epidemiology, University Medical Centre Groningen, University of Groningen, the Netherlands.
Karin E SmedbyUnit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.
Hans-Olov AdamiDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-171 77, Stockholm, Sweden.
Nicola S RussellDepartment of Radiotherapy, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Bengt GlimeliusDepartment of Pathology and Oncology, Karolinska Institutet, SE-171 77, Stockholm, Sweden.
Stephen Hamilton-DutoitInstitute of Pathology, Aarhus University Hospital, DK-8000, Aarhus, Denmark.
Marieke de BruinDepartment of Epidemiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
Lars P RyderDepartment of Clinical Immunology, University Hospital of Copenhagen, Rigshospitalet, DK-2100, Copenhagen, Denmark.
Daniel MolinDepartment of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden.
Karina Meden SorensenDepartment of Clinical Biochemistry, Statens Serum Institut, Copenhagen, Denmark.
Ellen T ChangCancer Prevention Institute of California, Fremont, CA 94538.
Malcolm TaylorCancer Immunogenetics Group, School of Cancer & Enabling Sciences, University of Manchester, Research Floor, St Mary's Hospital, Manchester, M13 9WL, UK.
Rosie CookeSection of Epidemiology, Institute of Cancer Research, Sutton, SM2 5NG, UK.
Robert HofstraDepartment of Genetics University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Helga WestersDepartment of Genetics University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.
Tom van WezelDepartment of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Ronald van EijkDepartment of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Alan AshworthThe Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK.
Klaus RostgaardDepartment of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
Mads MelbyeDepartment of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
Anthony J SwerdlowCancer Prevention Institute of California, Fremont, CA 94538.
Richard S HoulstonSection of Cancer Genetics, Institute of Cancer Research, Sutton, SM2 5NG, UK.
Institute of Cancer Research · GBStatens Serum Institut · DKUniversity of Glasgow · GBUniversity Hospital Cologne · DELeiden University Medical Center · NLUppsala University · SEKarolinska Institutet · SEStanford University · USUniversity Medical Center Groningen · NLUniversity of Groningen · NL

Funding

Breast Cancer Now BREAST CANCER NOW RESEARCH CENTRECancer Research UK A3351Cancer Research UK C1298/A8362Medical Research Council G0000934Wellcome TrustWellcome Trust 068545/Z/02Wellcome Trust 076113Wellcome Trust 085475
6 · The paper itself

Abstract

To identify susceptibility loci for classical Hodgkin's lymphoma (cHL), we conducted a genome-wide association study of 589 individuals with cHL (cases) and 5,199 controls with validation in four independent samples totaling 2,057 cases and 3,416 controls. We identified three new susceptibility loci at 2p16.1 (rs1432295, REL, odds ratio (OR) = 1.22, combined P = 1.91 × 10(-8)), 8q24.21 (rs2019960, PVT1, OR = 1.33, combined P = 1.26 × 10(-13)) and 10p14 (rs501764, GATA3, OR = 1.25, combined P = 7.05 × 10(-8)). Furthermore, we confirmed the role of the major histocompatibility complex in disease etiology by revealing a strong human leukocyte antigen (HLA) association (rs6903608, OR = 1.70, combined P = 2.84 × 10(-50)). These data provide new insight into the pathogenesis of cHL.

Indexed as

Genetic Predisposition to DiseaseGenome-Wide Association StudyAdultChromosomes, HumanChromosomes, Human, Pair 10Chromosomes, Human, Pair 2Chromosomes, Human, Pair 8FemaleGATA3 Transcription FactorGenetic LociGenome, HumanHodgkin DiseaseHumansMalePolymorphism, Single NucleotideProto-Oncogene Proteins c-relGATA3 protein, humanGATA3 Transcription FactorProto-Oncogene Proteins c-rel

Identifiers

PMID21037568
PMCPMC4268499
OpenAlexW2142363806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.